Amycretin
Amycretin (unimolecular GLP-1 / amylin agonist)
Also known as: Zenagamtide
Novo Nordisk's single-molecule GLP-1 and amylin agonist, in oral and injectable forms, that showed strong early weight loss and is heading to Phase 3.
Overview
Amycretin is a Novo Nordisk drug that combines GLP-1 and amylin activity in a single molecule, aiming to match combination therapy in one agent. It is being developed in both oral and injectable forms. Phase 2 reported around 14.5% weight loss at 36 weeks for the injectable in people with type 2 diabetes, and the earlier Phase 1b/2a obesity study reported 22% to 24% at 36 weeks. Update, September 2026: the Phase 3 AMAZE program began in February 2026 with AMAZE 1 in adults with overweight or obesity. It is investigational and not approved.
Mechanism of action
A single molecule that agonizes both the GLP-1 and amylin receptors to suppress appetite through two complementary pathways.
Key studies & citations
- Human2025
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study
125 participants: weight fell 22.0% (20 mg) and 24.3% (60 mg) at 36 weeks versus about 1% to 2% gain with placebo; GI events common.
The Lancet - Human2025
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1 trial
Oral amycretin first-in-human study establishing safety and early weight-loss signal.
The Lancet - Human2026
AMAZE 1: a research study investigating how well the medicine NNC0487-0111 helps people with excess body weight lose weight
Phase 3, 1,150 participants, started February 24, 2026, recruiting; primary completion mid-2029.
ClinicalTrials.gov
Frequently asked questions
How is amycretin different from CagriSema?
CagriSema combines two separate molecules (cagrilintide and semaglutide), while amycretin puts GLP-1 and amylin activity into a single molecule.